Filter by:
Rejuva
ADA, 2024
Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity
Rajagopalan, et al., presented at the American Diabetes Association’s 84th Scientific Sessions
Rejuva
DDW, 2024
Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity
Rajagopalan, et al., presented at Digestive Disease Week, Washington, D.C., May 2024
Rejuva
WCIRDC, 2023
Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity
Liou, et.al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Universal City, CA, Dec 2023
Rejuva
EASD, 2023
Pancreatic Gene Therapy Durably Improves Glycaemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes
Rajagopalan, et al. presented at European Association for the Study of Diabetes (EASD) 2023, Hamburg, German, October 2023
Rejuva
ADA, 2023
Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes
Rajagopalan, et al. presented at American Diabetes Association 2023, San Diego, CA, June 2023
Rejuva
ASGCT, 2023
A Pancreatic Gene Therapy Delivery Platform for the Treatment of Type 2 Diabetes
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
Rejuva
ASGCT, 2023
Local Delivery and Tissue Restricted Expression to Optimize Therapeutic Profile for Pancreatic Gene Therapy
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
Rejuva
WCIRDC, 2022
AAV-Mediated Pancreatic Gene Therapy for Type 2 Diabetes
Liou, et al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), Universal City, CA, Dec 2022
RejuvaRevita
AHA, November 2017
The Economic Burden of Insulin Resistance, Obesity, and Cardiovascular Disease in Medicare Beneficiaries 65 Years of Age and Older
Sacks, et al. presented poster at American Heart Association Meeting (AHA). Anaheim, Calif., USA, November 2017.